Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Jul 18, 2021; 11(7): 254-262
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.254
Chances and risks of sodium-glucose cotransporter 2 inhibitors in solid organ transplantation: A review of literatures
Marlene Schwarzenbach, Flavia Elena Bernhard, Cecilia Czerlau, Daniel Sidler
Marlene Schwarzenbach, Flavia Elena Bernhard, Cecilia Czerlau, Daniel Sidler, Department of Nephrology and Hypertension, University Hospital Insel Bern, Bern 3010, Switzerland
Author contributions: Czerlau C and Sidler D designed the study; Schwarzenbach M and Bernhard FE performed the literature search; Schwarzenbach M, Bernhard FE, Czerlau C and Sidler D wrote the paper.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniel Sidler, MD, PhD, Assistant Professor, Consultant Physician-Scientist, Senior Researcher, Department of Nephrology and Hypertension, University Hospital Insel Bern, Freiburgstrasse, Bern 3010, Switzerland. daniel.sidler@insel.ch
Received: January 11, 2021
Peer-review started: January 11, 2021
First decision: May 5, 2021
Revised: May 17, 2021
Accepted: May 26, 2021
Article in press: May 26, 2021
Published online: July 18, 2021
Core Tip

Core Tip: Literature review of efficacy and side effects of sodium-glucose cotransporter 2 inhibitors in diabetes management specifically in solid organ recipients.